Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoadsorption, current status and future developments.

N Braun1, T Bosch

  • 1Sektion Nieren-und Hochdruckkrankheiten, Medizinische Universitätsklinik und Poliklinik, Otfried-Müller-Str. 10, 72076 Tübingen, Germany. nbraun@uni-tuebingen.de

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Precise Measurement of the D^{0} and D^{+} Lifetimes at Belle II.

Physical review letters·2021
Same author

Search for B^{+}→K^{+}νν[over ¯] Decays Using an Inclusive Tagging Method at Belle II.

Physical review letters·2021
Same author

Comparative genomics of ESBL-producing Escherichia coli (ESBL-Ec) reveals a similar distribution of the 10 most prevalent ESBL-Ec clones and ESBL genes among human community faecal and extra-intestinal infection isolates in the Netherlands (2014-17).

The Journal of antimicrobial chemotherapy·2021
Same author

Search for Axionlike Particles Produced in e^{+}e^{-} Collisions at Belle II.

Physical review letters·2020
Same author

The current chemical biology tool box for studying ion channels.

The Journal of physiology·2020
Same author

Adapting epicutaneous patch testing protocols to assess immediate-type skin reactions.

International journal of cosmetic science·2020
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Extracorporeal immunoadsorption offers targeted removal of immune components for autoimmune diseases. Despite its potential, limited trials and reimbursement hinder widespread clinical adoption of this apheresis technology.

Area of Science:

  • Immunology
  • Medical Technology
  • Biochemistry

Background:

  • Autoimmune diseases are linked to immune system abnormalities.
  • Plasmapheresis lacks specificity, removing all plasma components.
  • Modern apheresis aims for targeted immune component elimination.

Purpose of the Study:

  • To review the immunological and technical basis of extracorporeal immunoadsorption.
  • To discuss the current clinical status of extracorporeal immunoadsorption for immune-mediated diseases.

Main Methods:

  • Review of immunological principles.
  • Analysis of technical aspects of extracorporeal immunoadsorption.
  • Evaluation of current clinical applications and limitations.

Related Experiment Videos

Main Results:

  • Extracorporeal immunoadsorption provides a more specific alternative to plasmapheresis.
  • Commercialization and clinical adoption have been limited since the 1980s.
  • Lack of controlled trials and reimbursement are key barriers.

Conclusions:

  • Extracorporeal immunoadsorption has a strong scientific basis for treating immune-mediated diseases.
  • Further research and improved reimbursement are needed for broader clinical use.
  • This apheresis technique holds promise for targeted immunomodulation.